These data are consistent with the in vitro data with MCF7-AROM1 cells, where more profound combination effects were observed with RAD001 in combination with letrozole, supporting a combination of AI rather than tamoxifen with RAD001 for the first-line treatment of ER+ BC. The gene discussed is ESR1; the disease is breast cancer.